Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation. - Wikidata - wikimedia - TriplyDB

Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation.

Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation.

http://www.wikidata.org/entity/Q37760897

about

Living donor liver transplantation does not increase tumor recurrence of hepatocellular carcinoma compared to deceased donor transplantation.Comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B: a systematic review.Neutrophil-lymphocyte ratio predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation.Immunotherapeutic potential of neutralizing antibodies targeting conserved regions of the HCV envelope glycoprotein E2.Immunoprophylaxis against and prevention of recurrent viral hepatitis after liver transplantation.Clinical-pathological analysis of hepatitis B virus recurrence after liver transplantation in Chinese patients.Persistent disparities in liver transplantation for patients with hepatocellular carcinoma in the United States, 1998 through 2007.

P2860

Q34067940-A00AC67B-8A49-498A-9C61-BB45158DA69C Q34712961-121FE7C2-9A32-42FD-A56F-C52C871D4CD0 Q37378982-1321D911-C993-46F3-B772-528B1C6F4504 Q37859393-90B32B5B-9C2E-4E83-89DB-32A976CC8A6C Q37982346-CE1A2C8A-A951-4215-B0BD-9C77EB943D46 Q42244681-08A2B471-24D9-4010-9AE5-B32E9210113E Q46566414-FAD6EE12-ABF7-4750-92E6-747E3A59F437

P2860

Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation.

http://www.wikidata.org/entity/Q37760897

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Current therapeutic strategies ...... n after liver transplantation.

@en

Current therapeutic strategies ...... n after liver transplantation.

@nl

type

label

Current therapeutic strategies ...... n after liver transplantation.

@en

Current therapeutic strategies ...... n after liver transplantation.

@nl

prefLabel

Current therapeutic strategies ...... n after liver transplantation.

@en

Current therapeutic strategies ...... n after liver transplantation.

@nl

P1433

Q37760897-46570601-05EE-44A4-98C2-3F19E49286B1

P1476

Q37760897-784DD352-92CA-432C-BDD0-0129790BBE1F

P2093

Q37760897-A7F41460-441B-41F2-B682-57D8FD9AA0A2

Q37760897-D0C66786-5A09-45F6-83B3-FDCE55E222F6

P2860

Q37760897-04465294-04A7-4E48-AE8B-7487FD0341A0

Q37760897-09D449B9-5C27-4A4B-9CC9-444424438A60

Q37760897-0A75B336-7663-4E71-872E-3FCB49903D26

Q37760897-0DF2D620-5B0B-4534-9B24-F418AA3C7A99

Q37760897-1020FDDC-E8F6-4663-85B6-326FA9486A89

Q37760897-11F00E95-6588-4C32-B859-E43E0D2F0251

Q37760897-11F6ECF4-EF38-4C0A-A19D-6F3C47FC64F8

Q37760897-15609CDD-7940-49FE-8A10-A74AF8B306A6

Q37760897-1A38D72B-226C-4821-8D43-5A2B6C8E5D89

Q37760897-1AACA9E3-B2CD-4F9D-8A5A-F2B407A68636

P304

Q37760897-2EDE3226-D0D4-41FC-9807-0DC6FD9F8723

P31

Q37760897-872AF59A-3B80-4CAE-AC98-65B434FEB7ED

P356

Q37760897-CD676D07-5749-4816-887E-17C8707E3F0E

P407

Q37760897-39F11BDB-4FD3-4E4C-8A89-683ACE7A8D14

P433

Q37760897-0CB6D66E-F222-4B73-A9FE-3451BECBEFD9

P478

Q37760897-F137D118-5EC8-4445-BE42-86B1C941A027

P577

Q37760897-8903A142-00C4-4F26-ACCC-4B18B96C284D

P5875

Q37760897-779C5E22-C8D5-4305-9B25-112D32D76DF5

P698

Q37760897-6D5EA019-F9A5-467E-A1F0-B07CDF339C8D

P921

Q37760897-BDD05246-9B07-452B-9DED-352F89BD3886

P932

Q37760897-3DEE0E0A-7362-4D2C-AA6C-E3568C77E760

P356

WJG.V16.I20.2468

P1433

World Journal of Gastroenterology

P1476

Current therapeutic strategies ...... n after liver transplantation.

@en

P2093

Li Jiang

http://www.w3.org/2001/XMLSchema#string

Lu-Nan Yan

http://www.w3.org/2001/XMLSchema#string

P2860

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient

Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis

Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization.

Retransplantation of patients with severe posttransplant hepatitis B in the first allograft.

Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation.

Comparison of famciclovir and lamivudine in the long-term treatment of hepatitis B infection after liver transplantation.

An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy.

Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review.

Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease

P304

2468-2475

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V16.I20.2468

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44631213

http://www.w3.org/2001/XMLSchema#string

P698

20503446

http://www.w3.org/2001/XMLSchema#string

P921

liver transplantation

P932

2877176

http://www.w3.org/2001/XMLSchema#string